Indeed, at least two proteins, ITPA and GPT2, are well-established therapeutic targets for rheumatoid arthritis and anxiety disorders with the FDA-approved inhibitors, azathioprine and phenelzine, respectively. The gene discussed is GPT2; the disease is rheumatoid arthritis.